951313-26-1
Chemical Structure
Nemonoxacin malate solution
Synonym(s): TG-873870 malate hemihydrate solution
- CAS No.: 951313-26-1
- Formula:C20H25N3O4·C4H6O5·1/2H2O
- Molecular Weight:514.54
SMILES: OC(CC(O)C(O)=O)=O.COC1=C2N(C3CC3)C=C(C(C2=CC=C1N4C[C@H](C[C@@H](C4)N)C)=O)C(O)=O.O.[1/2]
Biological Activity: Nemonoxacin malate solution is mainly composed of Nemonoxacin malate hemihydrate (HY-14956A). Nemonoxacin (TG-873870) malate is a nonfluorinated quinolone antibiotic. Nemonoxacin malate has broad-spectrum activity against Gram-positive, Gram-negative and atypical pathogens. Nemonoxacin malate can inhibit drug-resistant Streptococcus pneumoniae and Methicillin-resistant Staphylococcus aureus. Nemonoxacin malate can be used for the research of community-acquired pneumonia[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nemonoxacin malate solution | Nemonoxacin malate solution is mainly composed of Nemonoxacin malate hemihydrate (HY-14956A). Nemonoxacin (TG-873870) malate is a nonfluorinated quinolone antibiotic. Nemonoxacin malate has broad-spectrum activity against Gram-positive, Gram-negative and atypical pathogens. Nemonoxacin malate can inhibit drug-resistant Streptococcus pneumoniae and Methicillin-resistant Staphylococcus aureus. Nemonoxacin malate can be used for the research of community-acquired pneumonia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Guo B, Zhang J, Yu J, Wu X, Shi Y, Tsai CY. A liquid chromatography-tandem mass spectrometry assay for the determination of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, in human plasma and urine and its application to a single-dose pharmacokinetic study in healthy Chinese volunteers. Biomed Chromatogr. 2012 Nov;26(11):1333-40.
- [2]. Li Y, Zhu D, Sun S, Chang X, Cao Z, Yang Y, Fu X, Li X, Xu J, Zhu Y, Hui F, Xu X, Chen Z, Peng L, Ma Z, Mo B, Li C, Lv Y, Zhao L, Zhu G, He Y, Liu H, Chen J, Wang Y, Liang Y, Lu Y, Qin Z, Yang H, Zhang M, Wu S, Tong Z, Ye F, Xiao Z, Wang X, Qiu C, Kuang J, Huang H, Wang K, Ying K, Jin F, Lv X, Huang Y, Liu D, Wang W, Zhang Y. A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients. Int J Antimicrob Agents. 2024 Aug;64(2):107235.
